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Aims The ryanodine receptor (RyR2) is an intracellular Ca2+ release channel essential for cardiac excitation–contraction
coupling. Abnormal RyR2 channel function results in the generation of arrhythmias and sudden cardiac death. The
present study was undertaken to investigate the mechanistic basis of RyR2 dysfunction in inherited arrhythmogenic
cardiac disease.
Methods
and results
We present several lines of complementary evidence, indicating that the arrhythmia-associated L433P mutation disrupts
RyR2 N-terminus self-association. A combination of yeast two-hybrid, co-immunoprecipitation, and chemical cross-
linking assays collectively demonstrate that a RyR2 N-terminal fragment carrying the L433P mutation displays substan-
tially reduced self-interaction compared with wild type. Moreover, sucrose density gradient centrifugation reveals that
the L433P mutation impairs tetramerization of the full-length channel. [3H]Ryanodine-binding assays demonstrate that
disrupted N-terminal intersubunit interactions within RyR2L433P confer an altered sensitivity to Ca2+ activation.
Calcium imaging of RyR2L433P-expressing cells reveals substantially prolonged Ca2+ transients and reduced Ca2+
store content indicating defective channel closure. Importantly, dantrolene treatment reverses the L433P mutation-
induced impairment and restores channel function.
Conclusion The N-terminus domain constitutes an important structural determinant for the functional oligomerization of RyR2. Our
findings are consistent with defective N-terminus self-association as a molecular mechanism underlying RyR2 channel
deregulation in inherited arrhythmogenic cardiac disease. Significantly, the therapeutic action of dantrolene may occur
via the restoration of normal RyR2 N-terminal intersubunit interactions.
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1. Introduction
The cardiac ryanodine receptor (RyR2) is a key component of excita-
tion–contraction coupling, mediating rapid Ca2+ release from the
sarcoplasmic reticulum (SR). RyR2 channels are closed in the muscle re-
laxation phase, whereas inappropriate SR Ca2+ release causes deleteri-
ous effects on cardiac function. Indeed, RyR2 dysfunction leading to
diastolic SR Ca2+ leak has been associated with both genetic and
acquired cardiac disorders.1– 4 Mutations in the RyR2 gene, inherited
in an autosomal dominant fashion, have been linked to two diseases dis-
playing overlapping clinical phenotypes: catecholaminergic polymorphic
ventricular tachycardia (CPVT1) and arrhythmogenic right ventricular
dysplasia (ARVD2). Both disorders are associated with episodes of
potentially lethal arrhythmias triggered by emotional or physical stress
and exhibit a mortality rate of 30%. CPVT1/ARVD2 exhibits incom-
plete penetrance, that is, carriers of the same mutation display differ-
ences in the severity of symptoms and some remain completely
asymptomatic indicating the involvement of other factors or compensa-
tory mechanisms. The CPVT1 phenotype is manifested in the absence of
structural abnormalities, whereas ARVD2 is associated with progressive
degenerationandfibrofatty replacementof the right ventricular myocar-
dium.5,6 The two disorders may represent a variable phenotype of the
same disease, because the same mutation has been described as causa-
tive of both CPVT1 and ARVD2 in different patients.6 –8
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To date, around 150 arrhythmia-associated RyR2 mutations have
been reported, the vast majority of which are missense (http://www.
fsm.it/cardmoc/, 13 November 2014). RyR2 mutations tend to cluster
in three distinct regions: the N-terminus, a small central domain, and a
large C-terminal region. Most of the mutations studied induce gain-
of-function changes in RyR2, reflected by an increased sensitivity to
activation by physiological and pharmacological agonists including
Ca2+, caffeine, and cAMP-mobilizing agents.9 – 15 Reduction and loss-
of-function RyR2 mutations causative of CPVT1/ARVD2 have also
been described.13,16 This is reminiscent of central core disease, where
most RyR1 mutations are gain-of-function, but a few loss-of-function,
mutants have also been reported.17,18 Different molecular mechan-
ism(s) underlying RyR2 channel deregulation have been proposed, in-
cluding abnormal binding of FKBP12.6,12,15 reduced threshold for store
overload-induced Ca2+ release,10,19 and defective inter-domain inter-
actions.14,20 Although there are conflicting reports for a given mutation
that could be down to methodological differences, it is possible that
there is no single unifying hypothesis, with each RyR2 mutation differen-
tially affecting the diverse channel regulation mechanisms.
RyRs are the largest ion channels known, composed of four identical
subunits of 5000 amino acids. The C-terminal part contains the trans-
membrane domains that form a Ca2+-conducting pore and is also
believed to comprise the primary tetramerization determinant.21– 25
The large cytoplasmic N-terminal portion is required for regulation of
the pore and serves as a scaffold for accessory proteins, ions, and
other modulators.26 Communication of the stimulatory/inhibitory cyto-
plasmic signals to the channel pore is conveyed by long-range conform-
ation changes and interactions between structural and functional
domains. Recently, we identified a novel N-terminus intersubunit inter-
action within RyR2, which is conserved in mammalian RyR isoforms and
the related inositol trisphosphate receptor.27,28 We further presented
functional evidence, suggesting that RyR2 N-terminus tetramerization
is involved in the stabilization of the closed state of the channel.28
Given that the N-terminus is one of the three mutation hot spots, we
speculated that arrhythmia-linked mutations may have an effect on
N-terminus self-association and RyR2 channel function. In this study,
we find that a single missense mutation (L433P) has a profound effect
on tetramerization of both the isolated N-terminus domain and the full-
lengthprotein. Functional assays furtherdemonstrate that the RyR2L433P
channel is unstable, and it also displays altered Ca2+ dependence and
compromised channel closure. Remarkably, dantrolene, a drug used
to treat the RyR1-mediated neuromuscular disorder malignant hyper-
thermia (MH), has the ability to reverse the mutation-induced pheno-
type.
2. Methods
A detailed description is available in Supplementary Material online on the
Cardiovascular Research website. Unless otherwise stated, cumulative data
were derived from at least three independent experiments.
2.1 Yeast two-hybrid, co-immunoprecipitation,
and chemical cross-linking assays
Yeast two-hybrid (Y2H), co-immunoprecipitation (co-IP), and chemical
cross-linking assays were carried out as described in Zissimopoulos
et al.27,28 For the experiments performed to test the effect of dantrolene,
cell homogenates were incubated with 1 mM dantrolene for 1 h at 378C
prior to cross-linking. The optical density of relevant bands was determined
by densitometry using a GS-700 scanner (Bio-Rad) and the Quantity One
software (Bio-Rad). Statistical analysis was carried out using the GraphPad
Prism software; one-way ANOVA with Bonferroni post hoc test for
ambient conditions, Kruskal–Wallis test with Dunn’s post hoc test was
used for group comparison with unequal variance (P, 0.05 in Bartlett’s
test) for reducing conditions.
2.2 Sucrose density gradient centrifugation
Sucrose density gradient centrifugation was carried out as previously
described.28 For the experiments performed to test the effect of dantrolene,
all buffers were supplemented with dantrolene at 1 mM. Densitometry ana-
lysis was performed and the amount of RyR2 in each fraction was normalized
against the amount of input protein in the microsomes.
2.3 [3H]ryanodine binding
[3H]ryanodine-binding assays were performed as previously described.28
For the experiments to test the effect of dantrolene, samples were pre-
incubated in the presence of 1 mM dantrolene for 1 h at room temperature.
Sigmoidal dose–response curve fitting (four-parameter logistic equation
with bottom and top constrained to 0 and 100, respectively) and statistical
analysis were performed using the GraphPad Prism software.
2.4 Calcium imaging
HEK293 cells expressing mutant or wild-type (WT) RyR2 were loaded with
Fluo-3 AM (10 mM) for 1 h at 308C and immersed in Krebs–Ringer–Hein-
sleit solution (120 mM NaCl, 25 mM HEPES, 5.5 mM glucose, 4.8 mM KCl,
1.3 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgCl2, and pH 7.4) to initiate
waves. For the experiments to test the effect of dantrolene, cells were cul-
tured in the presence of 1 mM of the drug. Cells were imaged for 3 min at
high resolution (10 frames/s) using a LeicaRS5 confocal laser scanning micro-
scope, and Ca2+ handling parameters were quantified using the LAS-AF Lite
software (Leica Microsystems). For transient amplitude, duration, and store
load, statistical analysis was performed using one-way ANOVA with Bonfer-
roni post hoc test. The frequency of calcium transients (number of events per
recording) was analysed using the non-parametric (Kruskal–Wallis) test
with the Dunn post hoc test.
3. Results
3.1 The L433P mutation disrupts RyR2
N-terminus self-association
To test the effect of the L433P mutation on RyR2 N-terminus self-
association, we employed the Y2H system reporting on protein–
protein interactions in a living cell. The RyR2 N-terminus domain
(1–906 amino acids) was expressed in yeast as a fusion with GAL4
AD (AD4L constructs) or with DNA-BD (BT4L constructs). The inter-
action of the WT fragment with itself (BT4LWT + AD4LWT) was very
strong, as previously reported.28 Quantitative liquid b-galactosidase
assays indicated that the presence of the L433P mutation severely com-
promises RyR2 N-terminus self-interaction in situ (Figure 1A). In the het-
erozygote scenario (BT4LL433P + AD4LWT or BT4LWT + AD4LL433P),
the interaction between the mutant and WT fragments was reduced
by 85% compared with the self-interaction of the WT fragments
(BT4LWT + AD4LWT).
The interaction between mutant and WT RyR2 N-terminal fragments
was further assessed by co-IP assays following co-expression in mamma-
lian HEK293 cells. WT RyR2 N-terminus tagged with the HA epitope
(AD4LWT, residues 1–906) was immunoprecipitated with AbHA from
CHAPS-solubilized cell lysates under reducing conditions, and the pres-
ence of co-precipitated BT4L (residues 1–906 tagged with the cMyc
epitope) was analysed by western blotting using AbcMyc. Figure 1B
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shows that cMyc-tagged BT4LWT is efficiently co-immunoprecipitated
by AD4LWT and AbHA, whereas the non-specific binding is negligible
in the negative control with non-immune antibody. AD4LWT also
results in co-IP of BT4LL433P (Figure 1B); however, the amount of the
recovered mutant fragment is substantially lower than that of its WT
counterpart. Quantification using densitometry analysis (n ¼ 5) of the
amount of BT4LL433P or BT4LWT recovered in the AD4LWT immuno-
precipitate indicates that the presence of the L433P substitution in the
RyR2 N-terminus reduces its ability to interact with the WT fragment
by 60% (Figure 1B).
3.2 Dantrolene enhances RyR2L433P
N-terminus tetramerization
The effect of the L433P mutation on RyR2 N-terminus oligomerization
was tested by chemical cross-linking assays.28 BT4LL433P and BT4LWT
were expressed in mammalian HEK293 cells; cell homogenates were
reacted with glutaraldehyde and analysed by western blotting using
AbcMyc. For the WT fragment, we observed time-dependent tetramer
formation under both ambient and reducing conditions (Figure 2A and
D), in agreement with our previous report.28 Chemical cross-linking of
the BT4LL433P mutant fragment resulted in the appearance of the tetra-
mer; however, its abundance was rather low relative to WT (Figure 2B
andE). Cumulative data (n ≥ 6) following densitometry analysis demon-
strated that the presence of the L433P mutation resulted in an60% de-
crease in the tetramer-to-monomer ratio (Figure 2G, 60 min). This effect
was also seen under reducing conditions, where dithiothreitol (DTT,
10 mM) was usedprior tochemical cross-linking to reduce the endogen-
ous disulfide bonds that covalently link BT4L tetramers. Following DTT
pre-treatment, the tetramer-to-monomer ratio for BT4LL433P was
decreased by 60% compared with the WT fragment (Figure 2H,
60 min).
Dantrolene is a drug used for the treatment of the RyR1-mediated
neuromuscular disorder MH,29 and despite having no effect on WT
RyR2,30 dantrolene was reported to restore normal cardiac function
in RyR2-related cardiac disease.14,31– 34 Since its putative binding site is
contained within the RyR2 N-terminus (residues 601–620, identical
to RyR1 residues 590–609),35,36 we investigated the effects of dantro-
lene on RyR2 N-terminus oligomerization. BT4LWT and BT4LL433P,
expressed in mammalian HEK293 cells, were treated with 1 mM dantro-
lene prior to chemical cross-linking and analysed by western blotting.
Dantrolene treatment did not produce any appreciable effect on
BT4LWT tetramer formation (see Supplementary material online,
Figure S1). Remarkably, dantrolene induced a substantial increase in
BT4LL433P tetramer formation under both ambient and reducing condi-
tions (Figure 2C and F ). Cumulative data (n ≥ 6) following densitometry
analysis revealed that the drug increased the tetramer-to-monomer
ratio by approximately two-fold (Figure 2G and H, 60 min). These find-
ings suggest that dantrolene is able to partially reverse the L433P
mutation-induced defect in N-terminus self-association.
3.3 The L433Pmutation results in unstable
RyR2 tetrameric channels
The Y2H, co-IP, and chemical cross-linking experiments described
above indicate that the L433P mutation significantly impairs the ability
of the RyR2 N-terminus to form tetramers, but this remained to be
determined for the full-length protein. To test this, RyR2 oligomeriza-
tion was assessed by sucrose density gradient centrifugation of CHAPS-
solubilized HEK293 microsomes expressing the WT or mutant protein.
This technique separates proteins according to their size under non-
denaturing conditions, therefore allowing for non-covalent protein–
protein interactions to be retained. Western blot analysis of density
gradient fractions indicated that solubilized RyR2WT was almost exclu-
sively present in ‘heavy’ sucrose fractions (Figure 3A), a sedimentation
Figure 1 The L433P mutation impairs RyR2 N-terminus self-interaction in situ and in vitro. (A) In situ Y2H assays: protein interactions were assessed in
yeast co-expressing AD4L with BT4L constructs (RyR2 residues 1–906 tagged with GAL4 AD or DNA-BD, respectively) using quantitative liquid
b-galactosidase assays (n ¼ 5). Data are given as mean value+ SEM; statistical analysis was carried out using unpaired, two-tailed Student’s t-test. (B) In
vitro co-IP assays from HEK293 cells co-expressing AD4L with BT4L (RyR2 residues 1–906 tagged with HA or cMyc epitope, respectively). Left panel,
AD4LWT was immunoprecipitated with AbHA from CHAPS-solubilized cell lysates and the presence of co-precipitated BT4LWT/BT4LL433P was analysed
by western blotting using AbcMyc. ‘Normal Ab’ refers to non-immune rabbit IgG and serves as negative control; cell lysate, 1/50th of the volume processed in
IP samples, was included in the gel to assess protein expression. Right panel, cumulative data (n ¼ 5) following densitometry analysis; data are given as mean
value+ SEM; statistical analysis was carried out using paired, two-tailed Student’s t-test.
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profile consistent with the known tetrameric assembly of the channel,
whereas minimal monomer was detected in ‘light’ fractions. Notably,
the distribution of RyR2L433P was considerably different from RyR2WT,
with the mutant protein widely distributed over almost the entire
sucrose gradient (Figure 3B). Some RyR2L433P protein was indeed
detected in ‘heavy’ fractions (25–28%) corresponding to the tetramer,
but the mutant was enriched in ‘light’ sucrose fractions (15–17%) corre-
sponding to dissociated subunits. Quantification using densitometry
analysis (n ≥ 3) demonstrates that RyR2L433P forms substantially less
tetramers compared with RyR2WT (P, 0.05; Figure 3D and see
Supplementary material online, Figure S2). RyR2L433P channel tetramer
formation was also tested by [3H]ryanodine-binding assays under condi-
tionspromotingmaximumchannel activation (100 mMCa2+ and10 mM
caffeine) and reporting on the total number of functional tetrameric
channels. The amount of bound [3H]ryanodine for RyR2L433P was very
low relative to RyR2WT (16.3+ 2.0 vs. 39.7+2.4 fmol/mg, respective-
ly, P, 0.01), despite having equivalent protein levels of RyR2L433P and
RyR2WT expressed in HEK293 cells (see Supplementary material
online, Figure S3). Given that high-affinity ryanodine binding requires
an intact tetrameric RyR2 channel,37 the most plausible explanation is
that the RyR2L433P tetramer assembly is partially impaired, which is con-
sistent with the density gradient centrifugation profile.
We subsequently tested whether dantrolene treatment affects tetra-
mer stability of the full-length RyR2L433P. Using sucrose density gradient
centrifugation, we found that dantrolene results in substantial redistribu-
tion of the RyR2L433P sedimentation profile, with most of the protein
enriched in ‘heavy’ sucrose fractions resembling the RyR2WT pattern
(Figure 3C). Cumulative data (n ≥ 3) indicated that dantrolene shifted
the abundance of the RyR2L433P protein from ‘light’ sucrose fractions to
predominantly ‘heavy’ fractions, similar toRyR2WT (Figure3D andseeSup-
plementary material online, Figure S2). These findings suggest that dantro-
lene promotes tetramer stability of full-length RyR2L433P. Dantrolene
(1 mM) also resulted in a substantial (50%) increase in [3H]ryanodine
binding to RyR2L433P at 100 mM Ca2+ (13.8+1.7 vs. 20.7+2.4 fmol/mg
for dantrolene, P, 0.05), providing further evidence that the drug
enhances the functional tetrameric assembly of the mutant channel.
Figure 2 Dantrolene enhances tetramerization of L433P mutant RyR2 N-terminus. Chemical cross-linking assays of HEK293 cell homogenates expres-
sing BT4LWT (A and D) or BT4LL433P pre-treated without (B and E) or with 1 mM dantrolene (C and F ). Cell homogenates were incubated with glutaralde-
hyde for the indicated time points at ambient (A–C) or reducing (10 mM DTT) conditions (D–F ), and analysed by western blotting using AbcMyc; monomer
(M) and tetramer (T) are indicated with the arrows. Densitometry analysis (n ≥ 6) was carried out on the bands corresponding to tetramer and monomer
moieties, and used to calculate tetramer formation at (G) ambient or (H ) reducing conditions. Data are given as mean value+ SEM; statistical analysis was
carried out using one-way ANOVA with the Bonferroni post hoc test (G) or non-parametric (Kruskal–Wallis) test with Dunn’s post hoc test (H ).
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3.4 Defective RyR2L433P N-terminus
self-association underlies altered Ca21
sensitivity
To obtain some insights into the functional effects of the L433P muta-
tion, we tested the Ca2+ dependence of the mutant channel using
[3H]ryanodine-binding assays. Despite RyR2L433P tetramer instability
resulting in reduced ryanodine-binding capacity relative to RyR2WT,
the mutant channel was responsive to Ca2+ activation (Figure 4A). A
typical sigmoid Ca2+-dependence curve was obtained for RyR2L433P;
however, it was much flatter compared with WT. This might suggest
that the L433P mutation results in depressed channel activity at high
Ca2+ concentrations; however, this interpretation would be misleading
Figure 3 Dantrolene promotes oligomerization of the full-length RyR2L433P. Distribution of RyR2WT (A) or RyR2L433P pre-treated without (B) or with
1 mM dantrolene (C) in fractions collected following sucrose density gradient centrifugation. RyR2WT and RyR2L433P were expressed in HEK293 cells, and
CHAPS-solubilized microsomal membranes were subjected to sucrose density gradient centrifugation. The protein distribution profile was analysed by
western blotting using RyR2 Ab1093. Microsomes (25 mg, M) were also included to assess protein expression; sucrose concentration as indicated. Cumu-
lative data (n ≥ 3) following densitometry analysis are presented in (D); data are given as mean value+ SEM.
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because depressed [3H]ryanodine binding is more likely due to tetra-
meric assembly impairment. Normalization of L433P-binding data rela-
tive to its own maximum-binding value (obtained at 100 mM Ca2+)
produced a dose–response curve for RyR2L433P that is evidently left-
shifted relative to RyR2WT (Figure 4B), consistent with an increased
RyR2L433P sensitivity to Ca2+ activation with a significantly lower EC50
(EC50 ¼ 147.8 nM Ca2+ for RyR2L433P vs. EC50 ¼ 465.2 nM Ca2+ for
RyR2WT, P, 0.001).
The observed increased RyR2L433P sensitivity to Ca2+ activation
could be due to mutation-induced defective N-terminus self-
association. We have shown previously that the presence of exogenous
RyR2 N-terminus domain (BT4L) increases RyR2 channel activity at low
diastolic Ca2+ concentrations, most likely by disrupting the endogenous
N-terminal intersubunit interactions.28 Thus, BT4L can be used as a
probe to assess the state of N-terminal intersubunit interactions
within RyR2L433P. Western blot analysis of subcellular HEK293 fractions
showed that BT4L is expressed at similar levels when co-expressed with
the full-length RyR2L433P or RyR2WT (see Supplementary material
online, Figure S4). However, the amount of BT4L detected in the micro-
somal fraction was lower upon co-expression with RyR2L433P than with
RyR2WT, despite comparable RyR2 protein levels, indicating reduced
BT4L interaction with the mutant channel relative to WT. This is entirely
compatible with our Y2H and co-IP assays on the isolated N-terminal
fragments, described above. To ensure the presence of equivalent
BT4L protein levels, [3H]ryanodine-binding assays were carried out on
cell homogenates rather than microsomes. As previously observed,28
BT4L co-expression left-shifted the Ca2+ dose–response relationship
of RyR2WT (EC50 ¼ 470.9 nM Ca2+ for RyR2WT alone vs. EC50 ¼
280.6 nM for RyR2WT+ BT4L, P, 0.05; Figure 4C), indicating that
BT4L enhances the Ca2+ sensitivity of the channel. Notably, we found
no significant change in the dose–response curve of RyR2L433P upon
BT4L co-expression (EC50 ¼ 182.6 nM Ca2+ for RyR2L433P alone vs.
EC50 ¼ 129.2 nM for RyR2L433P+ BT4L, P ¼ 0.511; Figure 4D). Thus,
contrary to WT, the mutant L433P channel is not affected by BT4L, an
observation that is most probably due to the N-terminal self-association
within RyR2L433P already being disrupted.
Figure4 RyR2L433PdisplaysalteredCa2+ sensitivityduetodefectiveN-terminusself-association. (A) [3H]ryanodine-bindingassaysofRyR2WTorRyR2L433P
expressed in HEK293 cell homogenates, over a rangeof freeCa2+ concentrations. Summaryof three separate experiments eachperformedat least in duplicate.
Data are expressed as mean value+SEM; statistical analysis was carried out using unpaired, two-tailed Student’s t-test. (B) Ca2+ dose–response curve for
RyR2WT andRyR2L433P where the dataobtained in (A) are normalizedagainst maximum binding (100 mM Ca2+). TheEC50 values forCa
2+ activation, calculated
fromnonlinear regression analysis using theGraphPad Prism, were465.2 nMforRyR2WT vs. 147.8 nMforRyR2L433P,P, 0.001. (C)Adose–response curve for
Ca2+ dependence of [3H]ryanodine binding to RyR2WT alone and RyR2WT+ BT4L and normalized against maximum binding (100 mM Ca2+). The EC50 values
forCa2+ activationwere470.9 nMforRyR2WTalonevs. 280.6 nMforRyR2WT + BT4L(P, 0.05). (D)Dose–responsecurve forCa2+dependenceof [3H]rya-
nodine binding to RyR2L433P alone and RyR2L433P+ BT4L and normalized against maximum binding (100 mM Ca2+). The EC50 values for Ca2+ activation were
182.6 nM for RyR2L433P alone vs. 129.2 nM for RyR2L433P + BT4L (P ¼ 0.511).
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3.5 Dantrolene corrects abnormal
RyR2L433P intracellular Ca21 transients
To assess the effect of the L433P mutation on RyR2-mediated intracel-
lular Ca2+ handling, we employed a cellular assay developed by Jiang
et al.19 referred to as ‘store overload-induced Ca2+ release’. They
found that, at elevated extracellular Ca2+ levels resulting in Ca2+
store overload, HEK293 cells expressing RyR2 display spontaneous
Ca2+ release events in a manner indistinguishable from cardiac myo-
cytes. Untransfected cells that do not have endogenous RyR2 did
not display Ca2+ transients and did not respond to caffeine.19 To
monitor cytosolic Ca2+ transients, HEK293 cells transfected with
RyR2WT or RyR2L433P were loaded with the fluorescent Ca2+ indica-
tor Fluo-3 and were maintained in 1.3 mM extracellular Ca2+. Cells
expressing either the WT or the mutant RyR2 displayed spontaneous
Ca2+ transients but with two clear differences (Figure 5). First,
RyR2L433P-expressing cells displayed fewer Ca2+ transients compared
with RyR2WT (Figure 5, ‘number of events’ panel), most likely due to
the reduced number of functional channels and compatible with the
density gradient centrifugation and [3H]ryanodine-binding data
described above. Secondly, Ca2+ transients had substantially increased
duration and the Ca2+ store content, measured with application of
10 mM caffeine, was reduced in RyR2L433P-expressing cells compared
with RyR2WT. These observations are consistent with defective
RyR2L433P N-terminus self-association resulting in compromised
channel closure.
Totest the functionaleffectsofdantrolene, cellsweretreatedwith1 mM
of the drug and their Ca2+ handling properties were analysed by Ca2+
imaging. Dantrolene treatment had insignificant effects on RyR2WT-
expressing cells, but induced pronounced changes in RyR2L433P-mediated
Ca2+ mobilization (Figure 5). In particular, 1 mM dantrolene increased the
Ca2+ store content and the number of RyR2L433P Ca2+ transients, and
decreased transient duration to levels similar to RyR2WT. These findings
suggest that dantrolene restores WT channel function to RyR2L433P and
normalizes Ca2+ handling in cells.
4. Discussion
In the present study, we investigated the molecular mechanism under-
lying RyR2 channel dysfunction in arrhythmogenic cardiac disease.
Our major findings are: (i) the arrhythmogenic L433P mutation compro-
mises RyR2 N-terminus self-association resulting in defective channel
closure and (ii) dantrolene promotes N-terminus self-association
thereby restoring RyR2L433P channel function.
Figure5 Dantrolenenormalizes abnormal RyR2L433P-mediated Ca2+handling in cells. Single-cell Ca2+ imaging using confocal laser scanning microscopy
tomonitor intracellular Ca2+mobilization inRyR2-expressing cells. HEK293cells transfected withRyR2WT orRyR2L433P, and treated withorwithout1 mM
dantrolene, were imaged at 1.3 mM extracellular Ca2+ to induce spontaneous Ca2+- release transient events. The Ca2+ store content was estimated from
the amplitude of the (10 mM) caffeine-induced Ca2+ release at the end of each experiment. Ca2+ transient characteristics were analysed from 39 cells for
RyR2WT, 41 for dantrolene-treated RyR2WT, 29 for RyR2L433P, and 53 for dantrolene-treated RyR2L433P. Data are normalized for RyR2WT and expressed as
mean value+ SEM; statistical analysis was carried out using one-way ANOVA with the Bonferroni post hoc test (amplitude, duration, and store load) or
non-parametric (Kruskal–Wallis) test with Dunn’s post hoc test (frequency).
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4.1 The N-terminus domain is an important
structural determinant for RyR2
tetramerization
Using independent but complementary experimental techniques, we
found that the L433P mutation results in substantially reduced self-
association of the human RyR2 N-terminus domain (Figures 1 and 2).
This mutation cannot affect intersubunit interactions directly, because
it is buried within the three-dimensional structure of the RyR2
N-terminus.38 In particular, L433 lies within an a-helix, and its substitu-
tion for proline, a rigid body amino acid, is likely to disrupt the helix and
alter the structure locally. This may in turn induce allosteric rearrange-
ments within the RyR2 N-terminus, indirectly affecting the intersubunit
interface, as suggested for some RyR1 mutations.39
Moreover, density gradient centrifugation indicated that the full-length
RyR2L433P has reduced tetramer stability (Figure 3). This is further
supported by measurements of maximal [3H]ryanodine binding to
RyR2L433P, which was substantially decreased compared with WT
(despite equivalent protein amounts). It is generally believed that the
C-terminal region is necessary and sufficient for oligomerization of the
nativeRyR.This is based on observations that large RyR1/2C-terminal frag-
ments containing the transmembrane domains are able to form a Ca2+-
conducting pore and bind ryanodine,21,22,24,25 whereas the extreme cyto-
plasmic C-terminal tail is capable of tetramerization.40 In addition, RyR1
lacking the last 15 amino acids does not display high-affinity ryanodine
binding, an effect attributed to impaired tetrameric assembly.23 Recently,
wehavereportedthat theN-terminusofall threemammalianRyR isoforms
is also capable of tetramerization.27,28 Thepresent studydemonstrates that
the arrhythmia-linked L433P mutation disturbs the tetramerization of not
only the RyR N-terminus, but also the full-length protein. Although we
cannot exclude the possibilityof long-range alterations affectingC-terminal
domainorganization, themost likelyexplanation is that theN-terminus self-
association is a significant RyR oligomerization determinant contributing to
the tetrameric stability of the protein complex.
4.2 Defective N-terminus self-association
underpins RyR2L433P channel deregulation
Our functional studies suggest that defective N-terminus self-association
within the L433P mutant channel results in increased Ca2+ sensitivity
(Figure 4). Exogenous N-terminus domain (BT4L) was previously shown
to enhance native RyR2 [3H]ryanodine binding at low Ca2+ concentra-
tions most likely due to disruption of endogenous RyR2 N-terminal inter-
subunit interactions.28 This was also found in the current study with
BT4LWT lowering the EC50 for Ca
2+ activation of RyR2WT (Figure 4C).
In contrast, exogenous BT4LWT had a minimal effect on RyR2L433P
[3H]ryanodine binding (Figure 4D), and the EC50 for Ca
2+ activation of
the mutant channel was comparable to RyR2WT + BT4LWT, suggesting
that the N-terminal intersubunit interactions within RyR2L433P are
already disrupted. It was recently reported that RyR2L433P knock-in cardi-
omyocytes display increased Ca2+ spark frequency and SR Ca2+ leak.41
ThepresentcharacterizationofrecombinanthumanRyR2L433Pexpressed
in HEK293 cells, where prolonged Ca2+ transients and reduced Ca2+
store content were observed (Figure 5), concurs with the transgenic
mouse model. Based on these findings, we propose a model where
the arrhythmia-linked L433P mutation impairs N-terminal intersubunit
interactions resulting in defective channel closure (Figure 6).
Our findings indicate that the functional defect produced by the
L433P mutation is two-fold: (i) reduced number of functional channels
and (ii) increased Ca2+ sensitivity. The interplay between these two em-
pirical observations, which could have seemingly opposite effects,
namely depressed or enhanced Ca2+ mobilization, may explain the dis-
tinctive Ca2+ release profile previously reported for RyR2L433P and also
observed in the present study. Thomas et al.13 reported that, unlike
other CPVT1/ARVD2 mutations, RyR2L433P has reduced caffeine sensi-
tivity, which could be due to the reduced number of functional channels
(Figure 3). On the other hand, theyalso found that, similar to other muta-
tions, RyR2L433P channels result in increased Ca2+ release rate and pro-
longed Ca2+ transient,13 which could be due to enhanced Ca2+
sensitivity (Figure 4). We note that prolonged Ca2+ transients were
also observed in the present study (Figure 5), where Ca2+ mobilization
was induced by Ca2+ store overload instead of caffeine application.
The L433P mutation has also been functionally characterized by an inde-
pendent group, which reported increased propensity for spontaneous
Ca2+ oscillations due to enhanced luminal Ca2+ activation, similar to
other RyR2 mutations.10 Jiang et al.10 also reported no change in cyto-
plasmic Ca2+ activation for RyR2L433P, in disagreement with our
results. The reason for these discrepancies is unclear since we used
the same expression system (HEK293 cells) and functional assays
Figure 6 Working model for dantrolene rescue of defective RyR2 in CPVT1/ARVD2. Schematic representation of the putative role of N-terminus tetramer-
ization in stabilizing theclosedconformationof theRyR2channel. InCPVT1/ARVD2,N-terminal intersubunit interactionsaredefective, resulting in compromised
channel closure and prolonged Ca2+ mobilization. Dantrolene restores RyR2 N-terminus self-association and prevents excessive diastolic SR Ca2+ release.
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([3H]ryanodine-binding and store overload-induced Ca2+ release), but
it could be because of the different species of RyR2 characterized,
namely human vs. mouse. We note that although the human sequence
shows 97% overall identity (98% similarity) with the mouse RyR2 used
by Jiang and colleagues, there are several non-conserved substitutions
in the vicinity of L433 (residues 440–443, see Supplementary material
online, Figure S5), which form a flexible loop connecting two
a-helices,38 and this disparity could therefore result in local structural
differences.
Importantly, our present work identifies the putative mechanism
underlying RyR2L433P channel dysfunction, namely defective N-terminal
intersubunit interactions. This molecular defect is functionally mani-
fested as perturbed cellular Ca2+ handling with unique characteristics
(Figure 5). In particular, a reduced number of spontaneous Ca2+ transi-
ents would suggest a loss-of-function phenotype, whereas enhanced
Ca2+ transient duration would classify this mutation as gain of function.
Despite their lower frequency, prolonged Ca2+ transients resulted in
reduced Ca2+ store content implying that the L433P mutation is primar-
ily gain of function. It should be noted that we monitored spontaneous
RyR2L433P Ca2+ transients in non-cardiac cells, whereas in the cardio-
myocyte context, Ca2+mobilization is triggered by the action potential
and normal heart beating rate is fixed by the sinus node. Thus, the
reduced frequency of spontaneous events is likely to be less pertinent
in the pathogenesis of cardiac arrhythmias, compared with the increased
duration of the Ca2+ transient and the consequent decreased Ca2+
store content.
4.3 Dantrolene reverses the L433P
mutation-induced impairment and restores
channel function
Remarkably, we found that dantrolene was able to enhance the tetramer
formation of the L433P mutant RyR2 N-terminus domain (Figure 2) and
improve the tetrameric stability of the full-length mutant protein
(Figure 3). Moreover, dantrolene was found to normalize the abnormal
Ca2+mobilizationpattern incells expressingRyR2L433P (Figure5).Dantro-
lene was synthesized in 1967 as a new class of skeletal muscle relaxant and
since 1977 hasbeenwidely used to treat MH, a pharmacogenetic disorder
associated predominantly with RyR1 mutations.29 Although dantrolene
inhibits RyR1 channel activity, it has no effect on RyR2 either in native car-
diomyocytes or when heterologously expressed in HEK293 cells.30 The
drug-binding site has been mapped to residues 590–609 within RyR1,
which are identical to RyR2 residues 601–620; yet the WT RyR2 surpris-
ingly does not bind dantrolene.35,36 However, a number of recent studies
reported that dantrolene prevents the SR Ca2+ leak mediated from dys-
functional RyR2,14,31–34 in agreement with our present findings (Figure 5).
Collectively, these studies suggest that the dantrolene-binding site only
becomes accessible in the altered RyR2 conformation presented in
genetic or acquired cardiac disease.
It was previously postulated that the drug’s mechanism of action
involves stabilization of inter-domain interactions between the
N-terminal and central regions of RyR.14,32,33,42 However, a recent
study reported that the location of the dantrolene-binding site is distal
to the RyR2 central region, and it was suggested that dantrolene may
allosterically modulate the interaction between the N-terminal and
central domains.43 In light of our present observation of direct effects
on RyR2 N-terminus self-association, we propose that dantrolene’s
therapeutic effect is mediated by the restoration of the compromised
N-terminal intersubunit interactions within arrhythmogenic mutant
RyR2 (Figure 6). We should note that dantrolene was used in our
studies at 1 mM, a clinically relevant concentration since this drug
reaches a plasma concentration of 4.2 mg/L (12 mM) in MH patients.29
Dantrolene has not been associated with any deleterious effects on
cardiac contractility, and while its use is only temporary in MH, it is
chronically administered for the treatment of skeletal muscle spasticity.
The fact that dantrolene does not alter normal RyR2 and cardiac func-
tion, but affects only the diseased heart, is of particular importance for
its potential clinical application to attenuate arrhythmias.
4.4 Implications for CPVT/ARVD and heart
failure
Abnormal RyR2 channel regulation results in arrhythmias and has been
implicated in inherited (CPVT1/ARVD2) and acquired cardiac diseases
(heart failure).1– 4 A common defect is believed to be diastolic Ca2+
overload due to SR Ca2+ leak through dysregulated RyR2. This in turn
could result in Na+ influx via the plasma membrane Na+/Ca2+ exchan-
ger reaching a threshold for delayed after-depolarizations and triggered
arrhythmias.4,44 Here, we demonstrate that RyR2L433P results in sub-
stantially prolonged Ca2+ transients providing a potential explanation
for the generation of fatal arrhythmias. The RyR2 L433P mutation was
originally identified in members of one Italian family, where electrical in-
stability and cases of sudden cardiac death were reported.6 This muta-
tion has been classified as causative of ARVD2 because affected
patients displayed symptoms of right ventricle degeneration and fibrosis.
ARVD2 and CPVT1 have very similar clinical manifestation character-
ized by catecholamine-induced ventricular arrhythmias and both are
linked with RyR2 mutations that are also co-clustered in three hot
spots on the peptide sequence, suggesting that they may share
common mechanism(s) for channel dysfunction. Our present findings
on an ARVD2-linked mutation may therefore be applicable to CPVT1.
We note that prolonged Ca2+ transients and reduced Ca2+ store
content, observed for RyR2L433P, are hallmark features of heart
failure.3,45,46 Moreover, we show that dantrolene is able to normalize
cellular Ca2+ handling by restoring RyR2L433P N-terminus self-
association, a drug previously shown to stabilize RyR2 function and
prevent SR Ca2+ leak in failing cardiomyocytes.32,34 Thus, we propose
that defective N-terminal intersubunit interactions may be integral to
the molecular mechanism underlying RyR2 channel deregulation in
both genetic and acquired arrhythmogenic cardiac disease.
At present, it is unclear how a RyR2 mutation can lead to right ven-
tricle degeneration. Arrhythmogenic right ventricular cardiomyopathy
or dysplasia has been described as a disease of the desmosome,
because it is associated predominantly with mutations in desmosomal
proteins.47–49 ARVD has incomplete penetrance and highly variable
clinical manifestation, indicating that there is not a straightforward geno-
type–phenotype relationship. Arrhythmias can also appear early in the
disease before significant structural remodelling of the myocardium and
contractile dysfunction develop. Several mechanisms have been pro-
posed to explain the development of right ventricle dysfunction and
fibrofatty scar formation, including disruption of cell–cell adhesion,
gene transcription involved in adipogenesis, and cardiomyocyte
apoptosis. Perturbed Ca2+ handling due to dysregulated RyR2 leads
to apoptosis and cell loss,50 providing a potential explanation for the de-
velopment of ARVD by the RyR2 L433P mutation. It should be noted
that a RyR2L433P mouse knock-in model was recently generated, and
while it was found to display the CPVT phenotype (as well as atrial fib-
rillation), the heart did not present any structural abnormalities.41 It is
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also known that the same RyR2 mutation (e.g. A77V and R176Q) can
lead to either CPVT or ARVD,6– 8 suggesting the involvement of
additional factors associated with fibrofatty replacement of the right
ventricle. Indeed, it has been suggested that ARVD progression and
disease expression are due to the complex effect of multiple genetic
and/or epigenetic modifiers interacting with environmental factors
such as exercise or inflammation.49
In summary, we report on a novel molecular mechanism for the
pathogenesis of ARVD2, which is likely to stimulate further investiga-
tions on RyR2 dysfunction in inherited and acquired cardiac pathologies.
Our findings suggest that targeting defective RyR2 N-terminal intersu-
bunit interactions represents a potentially effective therapy for the
treatment of RyR2-related arrhythmogenic cardiac disease.
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